Chanyshev M D, Pustyl'niak V O, Guliaeva L F
Biomed Khim. 2012 May-Jun;58(3):310-7.
We have investigated the effect of polycyclic aromatic hydrocarbons (PAHs) on estrogen-metabolizing genes CYP1A1, CYP1B1, CYP19 and ERalpha and cyclin D1 genes, which control of cell division in estrogen-depended tissues. Treatment of rats with benzo(a)pyren (BP) or 3-methylcholantrene (MC) significantly up-regulated CYP1A1, CYP1B1 gene expression in liver, uterus and ovary, whereas alfa-naphthoflavone (alpha-NF) did not have any effect. The high level of aromatase gene (CYP19) expression was detected in ovary only. Treatment of rats with BP or MC significantly down-regulated expression of this gene (15- and 5,5-fold, respectively), whereas alpha-NF did not have any effect. BP produced an increase in ERalpha and cyclin D1 gene expression in rat liver. This effect was not seen with MC and alpha-NF. ERalpha and cyclin D1 mRNA levels were unchanged in uterus of rats after PAHs treatment. On the other hand, BP treatment caused an increase of the ERalpha and cyclin D1 mRNA levels (3,5- and 2,5-fold, respectively) in ovary, whereas MC and alpha-NF did not have any effects. Thus, our results give evidence for tissue-specific effects of PAHs on expression of genes, which participate in hormonal carcinogenesis. Moreover, the fact that BP and MC treatment affects the expression of estrogen-metabolizing genes and genes, which control of cell division, supports the view that PAHs may be one of the causes of endocrine disorder and consequent hormonal carcinogenesis.
我们研究了多环芳烃(PAHs)对雌激素代谢基因CYP1A1、CYP1B1、CYP19和ERα以及细胞周期蛋白D1基因的影响,这些基因控制着雌激素依赖组织中的细胞分裂。用苯并(a)芘(BP)或3-甲基胆蒽(MC)处理大鼠后,肝脏、子宫和卵巢中CYP1A1、CYP1B1基因表达显著上调,而α-萘黄酮(α-NF)则无任何影响。仅在卵巢中检测到高水平的芳香化酶基因(CYP19)表达。用BP或MC处理大鼠后,该基因的表达显著下调(分别下调15倍和5.5倍),而α-NF则无任何影响。BP使大鼠肝脏中ERα和细胞周期蛋白D1基因表达增加。MC和α-NF未出现这种效应。PAHs处理后,大鼠子宫中ERα和细胞周期蛋白D1的mRNA水平未发生变化。另一方面,BP处理使卵巢中ERα和细胞周期蛋白D1的mRNA水平增加(分别增加3.5倍和2.5倍),而MC和α-NF则无任何影响。因此,我们的结果证明了PAHs对参与激素致癌作用的基因表达具有组织特异性影响。此外,BP和MC处理会影响雌激素代谢基因以及控制细胞分裂的基因的表达,这一事实支持了PAHs可能是内分泌紊乱及随之而来的激素致癌作用原因之一的观点。